In the Biotech & Drugs group this morning, an analyst at Buckingham Research upgraded shares of Cephalon (Nasdaq: CEPH) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE